E-LIB Suche - Ergebnisse für: Peggs, K.

1

AVELUMAB MONOTHERAPY FOLLOWED BY A PET ADAPTED CHEMOTHERAPY..:

Collins, G. P. ; Hawkes, E. A. ; Kirkwood, A. A....
Hematological Oncology. 41 (2023) S2 - p. 162-163 , 2023

Link: https://doi.org/10.1002/..

2

179P Early proof of concept of safety and clinical activity..:

Forster, M.D. ; Cave, J. ; Greystoke, A....
Immuno-Oncology and Technology. 16 (2022) - p. 100291 , 2022

Link: https://doi.org/10.1016/..

3

ANIMATE: A PHASE II STUDY OF NIVOLUMAB IN TRANSPLANT ELIGIB..:

Booth, S. ; Kirkwood, A. ; Johnson, P....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

4

Current Practice in Vitamin D Management in Allogeneic Hema..:

Ros-Soto, J. ; Snowden, J.A. ; Salooja, N....
Biology of Blood and Marrow Transplantation. 25 (2019) 10 - p. 2079-2085 , 2019

Link: https://doi.org/10.1016/..

5

DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATI..:

Robinson, S. ; Boumendil, A. ; Finel, H....
Hematological Oncology. 37 (2019) S2 - p. 316-317 , 2019

Link: https://doi.org/10.1002/..

6

THE EFFICACY OF IBRUTINIB IN PATIENTS WITH RELAPSED MANTLE ..:

Burney, C.N. ; Robinson, S. ; Boumendil, A....
Hematological Oncology. 37 (2019) S2 - p. 243-244 , 2019

Link: https://doi.org/10.1002/..

7

Routine vaccination practice after adult and paediatric all..:

Miller, P D E ; de Silva, T I ; Skinner, R...
Bone Marrow Transplantation. 52 (2017) 5 - p. 775-777 , 2017

Link: https://doi.org/10.1038/..

8

RESULTS OF a MULTICENTRE UK‐WIDE STUDY EVALUATING THE EFFIC..:

Eyre, T.A. ; Phillips, E.H. ; Linton, K.M....
Hematological Oncology. 35 (2017) S2 - p. 82-83 , 2017

Link: https://doi.org/10.1002/..

9

TARGETING THE T‐CELL RECEPTOR Β‐CONSTANT DOMAIN FOR IMMUNOT..:

Maciocia, P.M. ; Wawrzyniecka, P. ; Philip, B....
Hematological Oncology. 35 (2017) S2 - p. 252-253 , 2017

Link: https://doi.org/10.1002/..

10

Erratum: Routine vaccination practice after adult and paedi..:

Miller, P D E ; de Silva, T I ; Skinner, R...
Bone Marrow Transplantation. 52 (2017) 7 - p. 1082-1082 , 2017

Link: https://doi.org/10.1038/..

11

BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALL..:

Bazarbachi, A. ; Boumendil, A. ; Finel, H....
Hematological Oncology. 35 (2017) S2 - p. 83-84 , 2017

Link: https://doi.org/10.1002/..

12

UK Cost-Effectiveness Analysis for Management of CMV Diseas..:

Nuijten, MJ ; Muller, H ; Kielar, C.
Value in Health. 19 (2016) 7 - p. A734-A735 , 2016

Link: https://doi.org/10.1016/..

13

Myeloablative versus reduced intensity allogeneic stem cell..:

Genadieva-Stavrik, S. ; Boumendil, A. ; Dreger, P....
Annals of Oncology. 27 (2016) 12 - p. 2251-2257 , 2016

Link: https://doi.org/10.1093/..

14

Analysis of outcome following allogeneic haemopoietic stem ..:

Hunter, H. M. ; Peggs, K. ; Powles, R....
British Journal of Haematology. 128 (2005) 4 - p. 496-502 , 2005

Link: https://doi.org/10.1111/..

15

Imatinib mesylate—gold standards and silver linings:

Peggs, K.
Clinical and Experimental Medicine. 4 (2004) 1 - p. 1-9 , 2004

Link: https://doi.org/10.1007/..